常茂生物化學工程股份有限公司

Changmao Biochemical Engineering Company Limited*

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 954)

UPDATE ON PROFIT WARNING

This announcement is made by Changmao Biochemical Engineering Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the profit warning announcement of the Company dated 19 April 2017 (the "**Previous Announcement**"). Unless otherwise defined, capitalised terms used herein shall have the same meaning as those defined in the Previous Announcement.

Based on the unaudited financial information currently available to the Board, the Board wishes to update the shareholders of the Company and potential investors that the Group is expected to record a decline of approximately 97% in the consolidated net profit attributable to the equity holders of the Company for the six months ended 30 June 2017 as compared to the consolidated net profit attributable to the equity holders of the Company of approximately RMB 20,716,000 for the six months ended 30 June 2016.

As mentioned in the Previous Announcement, the Board believes that the Group's financial performance for the six months ended 30 June 2017 ("**6M2017**") has been affected mainly by:

(i) the drop of profit margin of its products resulted from the significant increase in raw material price during 6M2017 as compared to that in the corresponding period in 2016; and

For identification purpose

(ii) the transformation of its maleic anhydride production lines with an existing annual production capacity of 20,000 tons in its Changzhou plant (the "**Transformation**"). Upon completion of the Transformation, butane instead of benzene will be used as a raw material to manufacture maleic anhydride. During the period of the Transformation, the production of maleic anhydride, a major raw material for the production of other major products of the Group, has to be temporarily suspended and the Group has to source maleic anhydride from external suppliers and incur extra energy costs such as steam cost and other manufacturing costs. Steam was a side product of the maleic anhydride production lines which was previously recycled for production of other products before the suspension. The Board considers that despite the adverse financial impact resulted from the temporary increase in production costs in the short-run, the Transformation is expected to have a cost saving advantage in the long run. The Group commenced the Transformation in March 2017. The Transformation of one of the maleic anhydride production lines with annual production capacity of 10,000 tonnes has been recently completed. It is currently expected that the completion of the Transformation of the remaining production line with an annual production capacity of 10,000 tonnes will be postponed to the fourth quarter of 2017 instead of the period of June to July 2017 as stated in the Previous Announcement because the construction time for the Transformation is longer than expected.

As the Company is still in the process of finalising the interim results of the Group for 6M2017, the information contained in this announcement is a preliminary assessment by the Board with reference to the management accounts of the Group for 6M2017 and the information currently available to the Company. Such information has not been audited or reviewed by the Company's auditor and/or the audit committee. Further details of the Group's performance will be disclosed when the Group's results for the six months ended 30 June 2017 are announced.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Changmao Biochemical Engineering Company Limited*
Rui Xin Sheng
Chairman

The PRC, 20 July 2017

**For identification purpose*

As at the date hereof, Mr. Rui Xin Sheng (Chairman) and Mr. Pan Chun are the executive directors of the Company, Mr. Zeng Xian Biao, Mr. Yu Xiao Ping, Mr. Wang Jian Ping and Ms. Leng Yi Xin are the non-executive directors of the Company, Prof. Ouyang Ping Kai, Prof. Yang Sheng Li, Ms. Wei Xin and Ms. Au Fung Lan are the independent non-executive directors of the Company.

**For identification purpose*